MonTa Biosciences today announced that the company has transitioned from a preclinical to a Clinical stage Biotech company. MonTa has today filed our first Clinical Trial Application in Europe and look forward to start treatment of the first patient with our lead candidate MBS8, in Q1, 2021. We will start the dose-escalation part of the study with two Danish sites and later expand into additional European sites. The trail will include MBS8 dosed in monotherapy and focus on safety, biomarkers and effect on tumor development. MBS8 is a novel TLR7 agonist formulated in micelles that show a strong antitumor activity, superior to other TLR7 agonists due to a different Mode of Action involving immediate migration of innate immune cells into tumor tissue and killing of tumor cells within hours. The Phase I trial is designed with two stages, stage I with a dose escalation phase and stage II with an expansion phase at the recommended phase 2 dose level.